Silence Therapeutics plc
SLN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479615
No open-market purchases or sales by Silence Therapeutics plc insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $236.2M in total; no superinvestor holds it.
Other share classesSLNCF
Q4 2021 vs. Q3 2021
How the institutions holding Silence Therapeutics plc changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 7 | 22 | +15 |
| Shares | 1.96M | 10.3M | +8.39M (+428.8%) |
| Value | $39.4M | $246.6M | +$207.3M (+526.6%) |
New holders (15)
Institutions that held Silence Therapeutics plc at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Deep Track Capital, LP | 950,798 | $22.7M | 1.68% |
| Frazier Management LLC | 886,173 | $21.2M | 1.63% |
| Goldman Sachs Group Inc | 760,000 | $18.2M | 0.00% |
| AXA S.A. | 661,666 | $15.8M | 0.04% |
| Great Point Partners LLC | 444,443 | $10.6M | 2.37% |
| Cantor Fitzgerald, L. P. | 254,519 | $6.08M | 0.44% |
| Point72 Asset Management, L.P. | 250,000 | $5.97M | 0.03% |
| HSBC Holdings PLC | 179,290 | $4.28M | 0.00% |
| UBS Group AG | 70,218 | $1.68M | 0.00% |
| Citigroup Inc | 58,333 | $1.36M | 0.00% |
| Bellevue Group AG | 46,666 | $1.09M | 0.01% |
| JPMorgan Chase & Co | 6,730 | $157.0K | 0.00% |
| Cubist Systematic Strategies, LLC | 184 | $4.00K | 0.00% |
| Steward Partners Investment Advisory, LLC | 100 | $2.00K | 0.00% |
| TCI Wealth Advisors, Inc. | 10 | $0 | 0.00% |
Sold out (0)
Institutions that held Silence Therapeutics plc at the end of Q3 2021 and filed for Q4 2021 without it.
None.